



## Novel Evidence Generating Tools for Precision Oncology

Guest Editors:

**Dr. Gennaro Daniele**

Phase 1 Unit, Fondazione  
Policlinico Universitario A.  
Gemelli IRCCS, 00168 Rome, Italy

**Dr. Rosa Falcone**

Medical Oncology, Policlinico  
Universitario Agostino Gemelli,  
UOC Fase 1 Largo Gemelli 8,  
00168 Rome, Italy

Deadline for manuscript  
submissions:

**closed (1 July 2022)**

### Message from the Guest Editors

Dear Colleagues,

The molecular dissection of cancer subtypes imposes a “new methodology” for assessing the safety and efficacy of novel drugs in specific cancer subtypes.

In recent years, different approaches have been used to face this need, with diverse results. Moreover, the possibility to use data coming from the real world for regulatory and developmental purposes can open completely new scenarios.

The purpose of this issue is to encourage discussion around and improve the visibility of all these points.

We look forward to receiving your contributions.

Dr. Gennaro Daniele

Dr. Rosa Falcone

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)